A novel tumor antigen derived from enhanced degradation of bax protein in human cancers

Cancer Research

Volumn 71, Issue 16, 2011, Pages 5435-5444

  Nunes, Cláudia Trindade ^a   Miners, Kelly L ^a   Dolton, Garry ^a   Pepper, Chris ^a   Fegan, Chris ^a   Mason, Malcolm D ^a   Man, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; EPITOPE; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BAX; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BINDING ASSAY; BLOOD SAMPLING; CANCER CELL; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SKIN FIBROSIS; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 80051701857     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0393     Document Type: Article

References (44)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
2. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27:6398-406.
3. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-5. (Pubitemid 30226050)
4. Magal SS, Jackman A, Ish-Shalom S, Botzer LE, Gonen P, Schlegel R, et al. Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J Gen Virol 2005;86:611-21. (Pubitemid 40331241)
5. Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM, et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006;126:1366-71. (Pubitemid 43997920)
6. Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Milligan D, et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol 2005;23:1514-21.
7. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935-8. (Pubitemid 27401947)
8. Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, et al. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood 2008;111:2790-6.
9. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008;111:2797-805.
10. Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999;18:2330-41. (Pubitemid 29213267)
11. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997;139:1281-92. (Pubitemid 27523214)
12. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
13. Andersen MH, Becker JC, Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005;4:399-409. (Pubitemid 40704123)
14. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005;6:181-8. (Pubitemid 40268199)
15. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7- specific CTL line. Int J Cancer 2005;114:606-12. (Pubitemid 40349620)
16. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001;167:5420-8. (Pubitemid 33009783)
17. Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 2005;17:167-76. (Pubitemid 40246581)
18. Devevre E, Romero P, Mahnke YD. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry. J Immunol Methods 2006;311:31-46.
19. Rowe M, Jones M. Detection of EBV latent proteins by western blotting. Methods Mol Biol 2001;174:229-42.
20. McCarthy C, Youde SJ, Man S. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. Int J Cancer 2006;118:2514-21.
21. Jochmus I, Osen W, Altmann A, Buck G, Hofmann B, Schneider A, et al. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J Gen Virol 1997;78:1689-95. (Pubitemid 27343109)
22. Fu NY, Sukumaran SK, Kerk SY, Yu VC. Baxbeta: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism. Mol Cell 2009;33:15-29.
23. Wood DE, Thomas A, Devi LA, Berman Y, Beavis RC, Reed JC, et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 1998;17:1069-78. (Pubitemid 28444591)
24. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003;9:4570-7. (Pubitemid 37248417)
25. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 1999;163:2928-36. (Pubitemid 29399225)
26. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934-43.
27. Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002;8:3885-92. (Pubitemid 35424784)
28. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995;92:432-6.
29. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 2000;97:4796-801. (Pubitemid 30238637)
30. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 2003;4:251-6. (Pubitemid 37329789)
31. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000;6:96-9. (Pubitemid 30048534)
32. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36. (Pubitemid 120035062)
33. Wang J, Sampath A, Raychaudhuri P, Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 2001;20:4740-9. (Pubitemid 32762445)
34. Castilleja A, Ward NE, O'Brian CA, Swearingen B, Swan E, Gillogly MA, et al. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem 2001;217:21-33. (Pubitemid 32184453)
35. Gileadi U, Moins-Teisserenc HT, Correa I, Booth BL, Dunbar PR, Sewell AK, et al. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J Immunol 1999;163:6045-52.
36. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997;185:909-20. (Pubitemid 27119875)
37. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, et al. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000;60:5508-13.
38. 264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:6929-37.
39. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res 2001;61:4072-7. (Pubitemid 32720973)
40. Maia S, Haining WN, Ansen S, Xia Z, Armstrong SA, Seth NP, et al. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res 2005;65:10050-8. (Pubitemid 41541487)
41. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004;61:2189-99. (Pubitemid 39280118)
42. Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007;110:2811-8. (Pubitemid 350006933)
43. + T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 2010;24:798-805.
44. van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006;18:98-104.